• Itron, Inc. recently announced a collaboration with France’s Office d'Equipement Hydraulique de Corse to upgrade 10,000 mechanical meters to its Intelis wSource ultrasonic solid-state water meters by 2030, aiming to improve measurement accuracy and support OEHC’s goal of preserving 5 million cubic meters of water annually by 2035.
• An important angle for investors is how this project showcases Itron’s role in tackling non-revenue water and enabling data-driven resource allocation, particularly where outdated infrastructure has left utilities billing for only about half of the water actually consumed.
• We’ll now explore how this large-scale ultrasonic meter rollout, with its focus on reducing non-revenue water, may influence Itron’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

Itron Investment Narrative Recap

To own Itron, you need to believe in long term adoption of smart metering and data driven utility operations, despite project and regulatory timing risks. The OEHC rollout reinforces Itron’s ability to address non revenue water, but on its own it does not appear to alter the near term reliance on large, backlog driven projects or the risk that approvals and utility budgets delay revenue.

Among recent updates, the Hunter Water pilot in New South Wales looks closest to the OEHC project, since it also uses Intelis wSource ultrasonic meters with Temetra MDM to address non revenue water. Together, these deployments highlight how water metering and software analytics could support Itron’s push toward higher value solutions, even as the company contends with slower Outcomes segment growth and customer decision delays.

Yet behind these smart water wins, one risk investors should be aware of is how prolonged regulatory and utility budgeting delays could...

Itron's narrative projects $2.7 billion revenue and $313.0 million earnings by 2029. This requires 5.0% yearly revenue growth and an earnings increase of about $24 million from $289.0 million today.

Uncover how Itron's forecasts yield a $126.70 fair value, a 57% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates for Itron range from US$72.87 to US$126.70, underscoring how far opinions can diverge. Set these against the risk that large, regulation heavy projects can slip in timing, and it becomes even more important to compare several independent views before deciding how this stock might fit into your portfolio.

Explore 4 other fair value estimates on Itron - why the stock might be worth 10% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Itron research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Itron research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Itron's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.